Bristol-Myers (BMY) Wins Ruling Blocking Generic Plavix
More News related to BMY
- ONGLYZA(TM) (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes
- 2009 Midyear New-Build Update: Pharmaceutical-Biotech Industry Completes Construction of 40 North American Facilities
- Medarex (MEDX) Higher After Experimental Drug Shows Dramatic Results
- June 23 DIA Sessions Chaired by SAFE-BioPharma Association
- Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
More News related to SNY
- Sanofi-aventis (SNY) Announes FDA Approval of Multaq for Patients with Atrial Fibrillation or Atrial Flutter
- FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Notable Analyst Rating Changes 6/29: DFS, LYG, TRW, BCS, JCP Upgraded; AA, SNY, BIIB, WW Downgraded
- J.P. Morgan Downgrades Sanofi-Aventis (SNY) to Neutral
- Sanofi-aventis Stands Behind the Safety of Lantus(R)
Bristol-Myers Squibb Co. (NYSE: BMY) and Sanofi-Aventis (NYSE: SNY) won a trial blocking generic competition on top selling blood-thinner Plavix. The court rejected Apotex\'s claim that the patent is invalid or unenforceable.
Related Categories
FDAStocks Mentioned
+7.35
-2.78Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
